pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Supportive Therapy

Oral Anticoagulant

  • Eg Warfarin
  • Oral anticoagulation is associated with improved survival in idiopathic pulmonary arterial hypertension (IPAH) patients & should also be considered in heritable pulmonary arterial hypertension (PAH), PAH due to anorexigen use & associated pulmonary arterial hypertension (APAH)
  • Anticoagulation in patients with PAH associated with underlying diseases such as scleroderma or congenital heart disease is controversial & one must consider risk-benefit ratio before starting Warfarin
  • Patients on long-term intravenous (IV) Epoprostenol in the absence of contraindications should be anticoagulated to prevent catheter-associated thrombosis
  • Therapeutic international normalized ratio (INR) can vary depending on the center: 1.5-2.5 or 2.0-3.0

Diuretics

  • Symptomatic & clinical benefits are seen in PAH patients with right heart failure
  • Choice & type of diuretics need to be individualized
  • Serum electrolytes & renal function should be monitored closely in those receiving diuretics

Digoxin

  • Digoxin produces favorable acute hemodynamic effects in patients with right heart failure & PAH with atrial tachyarrhythmia
    • Long-term benefits are unknown 
  • Use of Digoxin should be based on the judgment of the practitioner

Oxygen (O2) Therapy

  • Advised when oxygen saturation (SaO2) is consistently <60 mmHg to achieve SaO2 >60 mmHg for at least 15 hour/day
  • Ambulatory O2 may be given when there is improvement of symptoms & desaturation during exercise is corrected
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.